Claims for Patent: 7,717,853

Summary for Patent: 7,717,853

Title:	Methods and apparatus for intracranial ultrasound delivery
Abstract:	A method for delivering ultrasound energy to a patient\'s intracranial space involves forming at least one hole in the patient\'s skull, advancing at least one ultrasound delivery device at least partway through the hole(s), and transmitting ultrasound energy from the ultrasound delivery device(s). According to various embodiments, ultrasound delivery devices may be advanced into the epidural space, one or both ventricles and/or an intracerebral space of the patient\'s brain. In alternative embodiments, one or multiple holes may be formed in the skull, and any number of ultrasound delivery devices may be used. Intracranial ultrasound delivery may be used in diagnostic or therapeutic treatment of ischemic stroke, head trauma, atherosclerosis, perfusion disorders and other acute or chronic neurological conditions.
Inventor(s):	Nita; Henry (Redwood Shores, CA)
Assignee:
Application Number:	11/203,738
Patent Claims:	1. A method for delivering ultrasound energy to a patient's intracranial space, the method comprising: forming at least one hole in the patient's skull to access a target location; advancing at least one ultrasound device having a distal portion through the hole, wherein the distal portion contains at least one transducer to allow transmission of ultrasound, and the distal portion can be moved to various locations within the intracranial space without causing damage; transmitting ultrasound energy at frequencies between 20 Khz and 10 MHz from the ultrasound delivery device for therapeutic treatment; wherein the ultrasound energy is transmitted and directed from outside a blood vessel to a blood clot in the patient's brain at the target location that resides in an intracerebral space of the patient's brain, inside of the blood vessel, to disrupt the blood clot; further comprising placing an introducer device into the at least one hole, with the at least one ultrasound delivery device advanced through the introducer device. 2. The method of claim 1, wherein advancing the ultrasound device comprises advancing a device selected from the group consisting of an ultrasound transducer and a transducer-tipped ultrasound catheter. 3. The method of claim 1, wherein the ultrasound energy is transmitted acutely. 4. The method of claim 1, wherein the ultrasound energy is transmitted chronically. 5. The method of claim 1, further comprising delivering at least one pharmacologic agent to the patient. 6. The method of claim 5, wherein the agent is selected from a group consisting of blood clot reducing agents such as tissue plasminogen activator, rTPA, Urokinease, Streptokinase, Alteplase and Desmoteplase, antiplatelet agents such as aspirin, Clopidorgel and Ticciopidine, and GIIb/IIIa inhibitors, such as Abciximab, Tirofiban and Eptifibatide. 7. The method of claim 5, wherein delivering the agent comprises using a method selected from the group consisting of intravenous, arterial and oral delivery. 8. The method of claim 1, further comprising delivering microbubbles or nanobubbles into the patient's bloodstream. 9. The method of claim 8, wherein the microbubbles or nanobubbles are delivered intravenously or arterially. 10. The method of claim 8, further comprising providing at least one pharmacologic agent to the patient. 11. The method of claim 10, wherein the microbubbles or nanobubbles and pharmacological agent are delivered in combination or sequentially. 12. The method of claim 1, further including transmitting the ultrasound energy to a blood vessel in the patient's brain to help treat atherosclerosis of the blood vessel. 13. The method of claim 1, further including transmitting the ultrasound energy to one or more blood vessels in the brain to help treat a blood perfusion abnormality in the patient's brain. 14. The method of claim 1, further providing a conductive medium which interfaces between the ultrasound transducer and the patient. 15. The method of claim 14, further including providing the conductive medium in the form of a compliant pack. 16. The method of claim 15, further providing a gel or oil inside the pack. 17. The method of claim 1, further providing a conductive medium which interfaces between the ultrasound transducer and the patient. 18. The method of claim 1, further including transmitting ultrasound energy for cerebrovascular diagnostics. 19. The method of claim 1, further including transmitting ultrasound energy for cerebrovascular diagnostics and therapeutic treatment.

Details for Patent 7,717,853

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2039-03-29
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2039-03-29
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-03-29